Path AI is a global leader in AI-powered pathology solutions. Their comprehensive approach spans from wet lab services to algorithm deployment for clinical trials and diagnostic use. Essentially, they’re at the forefront of applying artificial intelligence to pathology, revolutionizing how we understand diseases.
PathExplore, their latest breakthrough, is a structured and scalable panel of human interpretable features (HIFs). These features provide an unprecedented resolution of the tumor microenvironment (TME) from whole-slide images. Powered by AI, PathExplore characterizes the TME with single-cell precision, enabling oncology drug developers to unlock critical insights for targeted therapy development.
The tumor microenvironment is a promising area of oncology research. By analyzing it, researchers can identify novel spatial signatures predictive of patient outcomes. PathExplore allows drug developers to dive deep into the TME while maintaining scalability across massive patient samples.
With PathExplore, the research paradigm shifts. It bypasses constraints seen in existing multi-omics methods, allowing open exploration and discovery of relationships that were previously hidden. Currently available for several cancer types, including breast, colorectal, and lung cancers, PathExplore aims to expand its indications to include ovarian and bladder cancers later this year.
Path AI’s commitment to precision pathology—from wet lab services to AI algorithms—holds immense promise. By bridging the gap between data and clinical decision-making, they empower oncologists, improve treatment strategies, and ultimately enhance patient car.
